In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
As of close of business last night, Sutro Biopharma Inc’s stock clocked out at $0.90, down -1.71% from its previous closing price of $0.92. In other words, the price has decreased by -$1.71 from its previous closing price. On the day, 0.62 million shares were traded.
Ratios:
To gain a deeper understanding of STRO’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.16 and its Current Ratio is at 2.16.
On March 14, 2025, Wedbush Downgraded its rating to Neutral which previously was Outperform and also lowered its target price recommendation from $8 to $2.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 1.14.
Stock Price History:
Over the past 52 weeks, STRO has reached a high of $5.17, while it has fallen to a 52-week low of $0.52. The 50-Day Moving Average of the stock is 12.07%, while the 200-Day Moving Average is calculated to be -61.54%.
Shares Statistics:
A total of 84.35M shares are outstanding, with a floating share count of 78.04M. Insiders hold about 7.60% of the company’s shares, while institutions hold 67.17% stake in the company.
Earnings Estimates
Currently, 1.0 analysts are dedicated to thoroughly evaluating and rating the performance of Sutro Biopharma Inc (STRO) in the stock market.The consensus estimate for the next quarter is -$0.45, with high estimates of -$0.45 and low estimates of -$0.45.
Analysts are recommending an EPS of between -$2.16 and -$2.16 for the fiscal current year, implying an average EPS of -$2.16. EPS for the following year is -$0.68, with 1.0 analysts recommending between -$0.68 and -$0.68.
Revenue Estimates
A total of 11 analysts have provided revenue estimates for STRO’s current fiscal year. The highest revenue estimate was $75.9M, while the lowest revenue estimate was $17M, resulting in an average revenue estimate of $56.78M. In the same quarter a year ago, actual revenue was $62.04M
